Internal Medicine, Hematology & Oncology · Valparaiso, IN
NPI
1194849901
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2600 Roosevelt Rd
Valparaiso, IN, 46383
Phone (219) 464-1620
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
151,166 services
Medicare patients, 2024
392
Average age 76
Drug cost, 2024
$5.6M
1,304 prescriptions
Company payments, 2025
$5,116
From 49 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Olusola Ogundipe was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 27,330 times for 14 patients. In total Olusola Ogundipe billed 151,166 services in 143 codes, and Medicare paid $2.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-16.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 27,330 | 14 | $2.36 | $64K |
| J0897 Injection, denosumab, 1 mg | Office | 8,880 | 30 | $20.75 | $184K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,330 | 11 | $1.35 | $7,196 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,500 | 14 | $15.31 | $23K |
| 36415 Venipuncture Blood Collection | Office | 1,291 | 232 | $8.65 | $11K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,274 | 23 | $0.09 | $113 |
| 85025 Blood Count | Office | 1,259 | 230 | $7.60 | $9,569 |
| 84132 Clinical Chemistry | Office | 1,237 | 225 | $4.66 | $5,764 |
| 84295 Clinical Chemistry | Office | 1,236 | 225 | $4.71 | $5,822 |
| 82435 Clinical Chemistry | Office | 1,236 | 225 | $4.51 | $5,574 |
| 82565 Clinical Chemistry | Office | 1,232 | 226 | $5.02 | $6,185 |
| 84520 Clinical Chemistry | Office | 1,230 | 226 | $3.87 | $4,760 |
| 82310 Clinical Chemistry | Office | 1,224 | 226 | $5.06 | $6,193 |
| 84075 Clinical Chemistry | Office | 1,224 | 226 | $5.08 | $6,218 |
| 82247 Clinical Chemistry | Office | 1,224 | 226 | $4.92 | $6,022 |
By year: 2022 $2.0M for 146,112 services; 2023 $1.7M for 106,402 services; 2024 $2.4M for 151,166 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,291 | 232 | $8.65 | $11K |
| 85025 Blood Count | 1,259 | 230 | $7.60 | $9,569 |
| 84132 Clinical Chemistry | 1,237 | 225 | $4.66 | $5,764 |
| 84295 Clinical Chemistry | 1,236 | 225 | $4.71 | $5,822 |
| 82435 Clinical Chemistry | 1,236 | 225 | $4.51 | $5,574 |
| 82565 Clinical Chemistry | 1,232 | 226 | $5.02 | $6,185 |
| 84520 Clinical Chemistry | 1,230 | 226 | $3.87 | $4,760 |
| 82247 Clinical Chemistry | 1,224 | 226 | $4.92 | $6,022 |
| 82310 Clinical Chemistry | 1,224 | 226 | $5.06 | $6,193 |
| 84075 Clinical Chemistry | 1,224 | 226 | $5.08 | $6,218 |
Medicare prescription drug claims, 2024
In 2024, the drug Olusola Ogundipe prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 96 prescriptions and refills. In total Olusola Ogundipe wrote 1,304 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 96 | 96 | Under 11 | $1.7M |
| Xarelto Rivaroxaban | 62 | 106 | 13 | $58K |
| Anastrozole Generic | 56 | 165 | 22 | $1,112 |
| Alprazolam Generic | 52 | 52 | 11 | $147 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 48 | 48 | Under 11 | $2,128 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 44 | 44 | 18 | $1,284 |
| Imbruvica Ibrutinib | 44 | 44 | Under 11 | $664K |
| Potassium Chloride Generic | 44 | 74 | 17 | $804 |
| Hydroxyurea Generic | 38 | 71 | Under 11 | $520 |
| Prednisone Generic | 38 | 76 | 15 | $271 |
| Gabapentin Generic | 32 | 36 | 11 | $462 |
| Eliquis Apixaban | 24 | 34 | Under 11 | $20K |
| Abiraterone Acetate Generic | 22 | 22 | Under 11 | $48K |
| Dexamethasone Generic | 22 | 22 | Under 11 | $281 |
| Brukinsa Zanubrutinib | 22 | 22 | Under 11 | $233K |
Brand drugs: 405 claims; generic drugs: 899 claims; opioid claims: 130.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Olusola Ogundipe $5,116 ($5,116 in general payments such as food, travel and fees) from 49 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,229.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 22 | $1,229 |
| AstraZeneca Pharmaceuticals LP AZN | 21 | $468 |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $449 |
| Merck Sharp & Dohme LLC MRK | 9 | $201 |
| GlaxoSmithKline, LLC. GSK | 7 | $141 |
| Abbvie Inc. ABBV | 7 | $136 |
| Exelixis Inc. EXEL | 4 | $118 |
| Genzyme Corporation SNY | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $104 |
| Daiichi Sankyo Inc. 4568.T | 4 | $101 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.